Difference between revisions of "Fostamatinib (Tavalisse)"
Jump to navigation
Jump to search
m (PeterYang moved page Fostamatinib (R788) to Fostamatinib (Tavalisse): FDA approval) |
(FDA approval) |
||
| Line 1: | Line 1: | ||
| − | = | + | ==General information== |
| − | + | Class/mechanism: Spleen tyrosine kinase (SYK) inhibitor. The main metabolite of fostamatinib is R406, which reduces antibody-mediated destruction of platelets. R406 also inhibits signal transduction of Fc-activating receptors and B-cell receptor.<ref name=insert>[http://tavalisse.com/downloads/pdf/Full-Prescribing-Information.pdf Fostamatinib (Tavalisse) package insert]</ref><ref>[[Media:Fostamatinib.pdf | Fostamatinib (Tavalisse) package insert (locally hosted backup)]]</ref><ref>[http://tavalisse.com/ Tavalisse manufacturer's website]</ref> | |
| + | <br>Route: PO | ||
| + | <br>Extravasation: n/a | ||
| − | = | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
| − | ==[[Diffuse large B-cell lymphoma]];[[Follicular lymphoma]]== | + | ==Diseases for which it is used== |
| + | *[[Autoimmune thrombocytopenic purpura (ITP)]] | ||
| + | *[[Diffuse large B-cell lymphoma]] | ||
| + | *[[Follicular lymphoma]] | ||
| + | |||
| + | ==Preliminary data== | ||
| + | ===[[Diffuse large B-cell lymphoma]]; [[Follicular lymphoma]]=== | ||
# Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 1;115(13):2578-85. Epub 2009 Nov 17. [http://www.bloodjournal.org/content/115/13/2578.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19965662 PubMed] | # Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 1;115(13):2578-85. Epub 2009 Nov 17. [http://www.bloodjournal.org/content/115/13/2578.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/19965662 PubMed] | ||
| + | |||
| + | ==Patient drug information== | ||
| + | *[http://tavalisse.com/downloads/pdf/Full-Prescribing-Information.pdf Fostamatinib (Tavalisse) package insert]<ref name="insert"></ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *4/17/2018: [https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604956.htm Granted FDA regular approval] "for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment." | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Code names:''' R788 | ||
| + | |||
| + | ==References== | ||
| + | <references/> | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
| + | [[Category:Hematology medications]] | ||
| + | [[Category:Immune thrombocytopenic purpura (ITP) medications]] | ||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:SYK inhibitors]] | [[Category:SYK inhibitors]] | ||
| − | + | [[Category:Drugs FDA approved in 2018]] | |
| − | [[Category: | ||
Revision as of 11:34, 19 April 2018
General information
Class/mechanism: Spleen tyrosine kinase (SYK) inhibitor. The main metabolite of fostamatinib is R406, which reduces antibody-mediated destruction of platelets. R406 also inhibits signal transduction of Fc-activating receptors and B-cell receptor.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Preliminary data
Diffuse large B-cell lymphoma; Follicular lymphoma
- Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010 Apr 1;115(13):2578-85. Epub 2009 Nov 17. link to original article PubMed
Patient drug information
History of changes in FDA indication
- 4/17/2018: Granted FDA regular approval "for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment."
Also known as
- Code names: R788